Komori
Veritas In Silico (130A) · RiskFirst stated

Three challenges for nucleic acid drugs: toxicity, manufacturing, and commercial viability

First written in FY2025. . Latest entry: FY2025.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Commercialization Challenges for Nucleic Acid Therapeutics: Toxicity, Manufacturing Costs, and Out-Licensing AttractivenessA theme 2 companies write about · 2 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025First statedAnnual report

    「We analyze the probability of completing Phase III trials after completing Phase II, filing an application and bringing a drug to market at only approximately 8–10% for nucleic-acid drugs, compared with approximately 40–50% for small-molecule drugs.」

    The company systematically identified for the first time 3 key challenges for nucleic-acid drugs: toxicity discovered in late-stage clinical development, manufacturing costs at commercial scale, and attractiveness to pharmaceutical companies as licensing-out opportunities. It also compared the probability of reaching the market after completion of Phase II for small-molecule and nucleic-acid drugs.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Veritas In Silico yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.